KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of “Moderate Buy” by Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given an average rating of “Moderate Buy” by the ten research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $26.4286.

A number of brokerages have recently commented on KALV. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. JMP Securities lifted their price objective on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th.

KalVista Pharmaceuticals Stock Down 1.0%

KalVista Pharmaceuticals stock opened at $10.78 on Friday. The company’s 50-day moving average price is $12.38 and its 200-day moving average price is $12.83. The company has a market cap of $544.64 million, a PE ratio of -2.74 and a beta of -0.04. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.21). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.97 million. As a group, sell-side analysts expect that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Paul K. Audhya sold 2,942 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $38,893.24. Following the transaction, the insider owned 119,841 shares of the company’s stock, valued at approximately $1,584,298.02. This represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 10,940 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $144,626.80. Following the sale, the chief executive officer directly owned 386,858 shares of the company’s stock, valued at $5,114,262.76. This represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 26,856 shares of company stock worth $374,910 over the last quarter. 4.30% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Earned Wealth Advisors LLC purchased a new stake in shares of KalVista Pharmaceuticals during the first quarter valued at $44,000. BNP Paribas Financial Markets lifted its holdings in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. CWM LLC lifted its holdings in KalVista Pharmaceuticals by 12,636.1% during the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after buying an additional 4,549 shares in the last quarter. Wolverine Asset Management LLC purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $57,000. Finally, KLP Kapitalforvaltning AS bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth about $63,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).